Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 27:15:1063-1072.
doi: 10.2147/CMAR.S294080. eCollection 2023.

Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data

Veronica Agostinelli  1 , Lucia Musacchio  2 , Floriana Camarda  2 , Vanda Salutari  2 , Maria Vittoria Carbone  2 , Viola Ghizzoni  2 , Camilla Nero  2 , Caterina Ricci  2 , Maria Teresa Perri  2 , Elena Giudice  3 , Sara Lardino  3 , Rossana Berardi  1 , Giovanni Scambia  2   3 , Domenica Lorusso  2   3
Affiliations
Review

Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data

Veronica Agostinelli et al. Cancer Manag Res. .

Abstract

Cervical cancer is the fourth most common type of cancer in women worldwide. It is associated with a high death rate, despite the fact that it is a nearly 100% preventable disease because of very effective primary and secondary preventive strategies. Advanced and recurrent disease is uncurable with a high relapse risk and the second-line therapies are limited with modest response rates and short durability. Investigating alternative mechanisms of action is crucial because of the high request for effective new therapies. Tisotumab vedotin (TV) is the first antibody-drug conjugated to target a cell surface-expressed tissue factor, and preliminary data in patients with metastatic and recurrent cervical cancer have been promising. In addition, the trials showed a favorable tolerability profile, with limited incidence of grade 3 or worse adverse events. According to the data of ENGOT-cx6/GOG-3023/innovaTV 204, the US Food and Drug Administration granted expedited approval of TV on September 20, 2021, for women with recurrent or metastatic cervical cancer. Actually, two other trials testing TV alone or in combination with other agents are ongoing. ENGOT-cx8/GOG-3024/innovaTV 205 is a Phase Ib/II trial of TV in combination with platinum or bevacizumab or pembrolizumab, in patients with recurrent or metastatic cervical cancer who have not received prior systemic therapy or who have progressed after no more than two prior systemic therapies. ENGOT-cx12/GOG-3057/InnovaTV 301 is a Phase 3 trial of TV vs investigator's choice chemotherapy in patients with advanced or recurrent cervical cancer who had received no more than 2 prior chemotherapy lines. The outcomes of these two trials will potentially confirm and reinforce the use of TV as a new standard of care in advanced or recurrent cervical cancer.

Keywords: antibody–drug conjugate; cervical cancer; gynecological cancer; tissue factor.

PubMed Disclaimer

Conflict of interest statement

V.S. reports grants and personal fees from: Clovis Oncology, GlaxoSmithKline, AstraZeneca, Merck Sharp & Dohme, PharmaMar, Novocure, outside the submitted work. R.B. reports personal fees from Boehringer, EISAI, Otsuka, Lilly, GSK, PharmaMar, Novartis, Amgen, GSK, and Gilead; grants from MSD, Roche, and Astra Zeneca, outside the submitted work. G.S. reports personal fees from: ROCHE, Clovis Oncology, AstraZeneca, PharmaMar, GlaxoSmithKline, outside the submitted work. He also reports grants from MSD Italia S.r.l.; personal fees from TESARO Bio Italy S.r.l, Johnson & Johnson, outside the submitted work. D.L. reports research funding from: Clovis Oncology, AstraZeneca, Corcept Therapeutics, GlaxoSmithKline, Genmab, ImmunoGen, Merck Sharp & Dohme, Novartis, PharmaMar, Roche, and Seagen; reports consulting fees from: Clovis Oncology, AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Oncoinvest, Corcept, Sutro, and PharmaMar; reports payment or honoraria for lectures from: Clovis Oncology, AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme, and Seagen; reports support for attending meetings and/or travel from: AstraZeneca, PharmaMar, and Roche; Participation on a data safety monitoring board or advisory board: Clovis Oncology, Agenus, AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, and Roche; and serves on the board of directors for GCIG and as chair of GCA for ENGOT, outside the submitted work; The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Mechanism of action of tisotumab vedotin.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660 - DOI - PubMed
    1. Cancer Stat Facts: Cervical Cancer. National cancer institute. Available from: https://seer.cancer.gov/statfacts/html/cervix.html. Accessed January 11, 2023.
    1. Neoplasie dell’utero: endometrio e cervice [Neoplasia of the uterus: endometrium and cervix]. September, 2022. Available from: https://www.iss.it/documents/20126/8403839/LG-486-AIOM_Ca-Cervice-Endome.... Accessed 11 January 2023
    1. Cibula D, Pötter R, Planchamp F, et al. The European Society of Gynaecological Oncology/European Society for radiotherapy and oncology/European society of pathology guidelines for the management of patients with cervical cancer. Int J Gynecol Cancer. 2018;28(4):641–655. doi:10.1097/IGC.0000000000001216 - DOI - PubMed
    1. PATH. Global HPV vaccine introduction overview: projected and current national introductions, demonstration/pilot projects, gender-neutral vaccination programs, and global HPV vaccine introduction maps (2006–2023) PATH; 2022. Available from: https://www.path.org/resources/global-hpv-vaccine-introduction-overview/. Accessed January 11, 2023.